SELLAS Life Sciences Group, Inc.
SLS
$1.41
$0.010.71%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 17.20% | 23.30% | 15.50% | 13.80% | 10.80% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -16.64% | -22.11% | -29.55% | -1.76% | 55.47% |
| Change in Net Operating Assets | -134.88% | -171.11% | -544.37% | -9.31% | -24.70% |
| Cash from Operations | -48.25% | -13.26% | -27.97% | 11.26% | 6.35% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -97.89% | 36,362.96% | -- | 40.95% | 267.81% |
| Repurchase of Common Stock | -106.45% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.76% | 36,362.96% | 1,527.59% | 40.95% | 264.48% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -396.53% | 220.80% | 8.19% | 134.40% | 65.92% |